In recent years there has been an increase in the number of reports in the U.S. of the use of drugs to commit sexual assault. In 1994, a nationwide urine testing program was developed to assess the incidence of the use of drugs to facilitate sexual assault and provide information for use in the investigation of these crimes. Urine samples were collected from victims of suspected druginduced sexual assault by law enforcement agencies, emergency rooms, and rape crisis centers. The most implicated drug class was benzodiazepines, either alone or in combination with alcohol. In this report, a procedure was developed for the screening of 22 benzodiazepines in human urine by liquid chromatography-time of flight-mass spectrometry [LC-MS-(TOF)]. The limit of quantitation for all benzodiazepines ranged from 2 to 10 ng/mL, and the limit of detection was 0.5 to 3.0 ng/mL. These results suggest that the method sensitivity is suitable to screen for all 22 benzodiazepines in human urine at low levels. The method was used to analyze samples previously reported to have screened positive for benzodiazepines by immunoassay at 50 ng/mL cut off but failed to confirm by a gas chromatography-MS method. The results of reanalysis of these samples using this LC-MS method are reported.
Introduction
In recent years there has been an increase in the number of reports in the U.S. of the use of drugs to commit sexual assault (1) (2) (3) (4) (5) (6) (7) (8) (9) . The media have developed the term "date-rape drugs" to describe the substances used by perpetrators to intoxicate potential victims, rendering them defenseless to sexual assault, with less ability to recall the event (10) .
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Roche Pharmaceuticals, the manufacturer of the drug Rohypnol | (flunitrazepam), the drug first implicated in those cases, took a number of steps to minimize the potential for abuse of its product and actively collaborated with international drug regulatory and law enforcement agencies. The company sponsored a testing program that offered wholly independent urine analyses to victims of alleged sexual assault in the United States. Urine samples were collected from suspected victims by law enforcement agencies, emergency rooms, and rape crisis centers. Most of the urine samples were taken from these individuals within 72 h of the reported incident, a time frame where rohypnol metabolites would be detected by the gas chromatography-mass spectrometry (GC-MS) method developed for this purpose (11) . The samples were collected between May 1996 and February 2000, and stored at -20~ until tested. All specimens were screened by OnLine immunoassay (Roche Diagnostic, Indianapolis, IN) for nine different drug classes. A previously published procedure was followed for benzodiazepine assay using a 50 ng/mL cutoff and ~-glucuronidase pretreatment (12) . Specimens were screened by a second immunoassay for benzodiazepines either by TestStik or OnTrack, both manufactured by Roche. These assays have a different cross-reactivity profile as compared to OnLine immunoassay. All specimens were analyzed for flunitrazepam metabolites following the GC-MS procedure developed by EISohly et al. (11) . The benzodiazepine GC-MS confirmation procedure was based on acid hydrolysis of the urine samples, which converts all the benzodiazepines having a similar basic skeleton to the same benzophenone. The benzophenones confirmed by GC-MS were those derived from oxazepam, diazepam, alprazolam, lorazepam, triazolam, nitrazepam, bromazepam, and norfludiazepam. A total of 3303 samples were analyzed. No drug was detected in 1277 samples (38.7%), and the remaining 61.3% of the samples showed positive results for one or more drugs. Benzodiazepines, as a general class, were detected in 313 cases (9.5% of all the specimens collected) (13). GC-MS confirmed most of the samples (71.7%) as oxazepam and/or diazepam subclasses because these subclasses have the most common basic skeleton for most benzodiazepines. There were 304 samples out of the 313 positive for 502 individual benzodiazepines, indicating multibenzodiazepine positives within the same sample (13). A total of 97 specimens did not confirm using the GC-MS procedure. Whether the lack of confirmation was because of the low level of benzodiazepine metabolites or because of a non-specific reaction of the immunoassay was not evident. We have therefore embarked on the development of a more specific and sensitive procedure that could be extended to a large number of benzodiazepines.
We herein report a simple liquid chromatography-time-offlight-MS [LC-MS-(TOF)] procedure for the determination of 22 benzodiazepines in human urine and its application for the analysis of 13 of these specimens that screened positive but were not confirmed by GC-MS. Table I. VWR (West Chester, PA). Sodium carbonate, HCI, acetonitrile, and gIacial acetic acid were purchased from Fisher Scientific (Fair Lawn, N J). Water for the LC mobile phase was purified in a Milli-Q system (Millipore, Bedford, MA).
Experimental Materials
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Urine samples
Urine samples were collected from suspected victims of drug-facilitated sexual assault by law enforcement agencies, emergency rooms, and rape crisis centers. Most of the urine samples were collected from these individuals within 72 h of the reported incident. The samples were collected between June 1996 and February 2000, and were stored at -20~ All specimens were first screened by OnLine immunoassay for different drug classes: amphetamines, barbiturates, benzodiazepines, benzoylecgonine, cannabinoids, methaqualone, opiates, phencyclidine, and propoxyphene (14) . Any specimen screening positive for any drug class was further tested for confirmation by GC-MS analysis. To increase the probability of detecting any benzodiazepines present, the specimens were screened by a second immunoassay with a different cross-reJournal of Analytical Toxicology, Vol. 30, October 2006 activity profile. Specimens screening positive that did not confirm by GC-MS were reanalyzed in this study.
Extraction
Extraction of free benzodiazepines [for calibration curve and limits of detection (LOD) and quantitation (LOQ)]. To 1.0 mL of blank urine in a 15-mL centrifuge tube were added 20 pL of internal standard solutions (5 pg/mL), an appropriate volume of the drug stock solutions (2 pg/mL), and then I mL of a 40% potassium phosphate buffer (pH 9). The pH was checked (pH paper) and adjusted to pH 8-10, when necessary, using drops of 2N NaOH. Chloroform/IPA (9:1) (4 mL) was added to each tube. The tubes were then capped and gently shaken for 2 min. The aqueous (top) layer was aspirated and discarded. The organic (bottom) layer was transferred to 13 • 100-ram culture tubes. The solvent was evaporated under nitrogen at 50~ to a volume of approximately I mL. This volume was then transferred to an LC vial and evaporated to dryness. The residue was reconstituted with 100 pL of methanol and transferred to LC vial inserts for LC-MS analysis. 0.00 50~0 100~00 15Q00 L~(~00 25000 300.00 3~000 400.00 4~00 50000 
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Hydrolysis and extraction of conjugated benzodiazepines (samples). To 1.0 mL of urine in a 15-mL centrifuge tube was added 20 IJL internal standard solutions (5 IJg/mL). Calibrators were prepared by spiking blank urine using the appropriate volume of the drug stock so]utions (2 ~ug/mL) and 20 pL of internal standard solutions (5 ~g/mL). To all tubes was then added 1.0 mL of sodium acetate buffer (pH 5.2), and the pH was checked and, if necessary, 1N HC1 was added to adjust the pH to 5-6. One-hundred microliters of [3-glusulase (glucuronidase > 90,000 units/mL and sulfatase > 10,000 units/mL) was added to each tube. The tubes were then lightly capped and placed in an oven at 37~ for 4 h, after which time 1 mL of 1.5M sodium carbonate buffer was added to each tube. Chloroform/IPA (9:1) (4 mL) was then added to each tube, and the tubes were shaken for 2 rain. The aqueous (top) layer was aspirated and discarded. The organic (bottom) layer was transferred into a 13 x 100-ram culture tube, and the solvent was evaporated under nitrogen at 50~ to a volume of approximately 1 mL. This volume was then transferred to an LC vial and evaporated to dryness. The residue was reconstituted with 100 I~L of methanol and transferred to LC vial inserts for analysis.
Instrumentation and chromatographic conditions
The LC used was an Agilent (Palo Alto, CA) series 1100 comprised of the following modular components: quaternary pump, a vacuum solvent microdegasser, an autosampler with 100-well tray and an online DAD. The MS analysis was performed on an Agilent series 1100 SL equipped with an ESI source. All acquisitions were performed under positive ionization mode with a capillary voltage of + 4000 V over a mass range of 200-1300 amu. Nitrogen was used as the nebulizer gas (30 psig) as well as the drying gas at a 10 L/rain at a drying gas temperature of 325~ Data acquisition and processing was done with the software Analyst TM QS (Agilent Technologies). Separation was achieved on a Luna C8 (2) column (100 x 4.6-ram i.d., 3-]Jm particle size, Phenomenex). The column was equipped with a guard column (Supelco, BelIefonte, PA). The mobile phase consisted of mixture of water (0.1% acetic acid) (A) and acetonitrile (0.1% acetic acid) (B). At a flow rate of 0.3 mL/min, a gradient elution was as follows: 73% A/27% B to 40% A/60% B at 50 min. Each run was followed by a 5-min wash with 100% acetonitrile and an equilibration period of 15 rain. The DAD was programmed to acquire the UV-spectra from 190 to 400 nm (step size 4 nm).
Extraction efficiency
In order to calculate the extraction efficiency (recovery) of the method, known quantities of the individual benzodiazepines were added to two sets of urine samples. One set of the spiked samples was extracted first and then the internal standards were added to the extracts. To the second set, the internal standards were added prior to extraction. All samples were then analyzed using the LC-MS method described. The % recovery was determined by comparing the drug/I.S, peak-area ratio in the first set to the ratio in the second set. containing 0.1% acetic acid as the mobile phase.
Method validation
Calibration curves, LODs, and LOQs. Quantification of the benzodiazepines was achieved with the use of internal standards. Calibration curves for all standard compounds were constructed in the range of 10-500 ng/mL (Figure 1) lowed the calculation of benzodiazepines concentration in various urine samples. The LOD and LOQ were calculated for a signal-to-noise (S/N) ratio of 3 and 10, respectively. The results are shown in Table I were used in this procedure, and the intra-and interday precision and accuracy values were determined by analyzing blank urine samples spiked with 1-22 standard solutions at two different concentrations (50 and 100 ng/mL). The intraday CV for the 100 ng/mL samples (n = 5) ranged from 0.12 to 4.62% for all drugs tested. The day-to-day CV for the 50 ng/mL samples (n = 6) ranged from 0.51 to 5.37%, and that for the 100 ng/mL samples (n = 6) ranged from 0.46 to 5.19% . lution of analytes on the analytical column is much less importance than with other techniques. There was no attempt, however, to compare this technique with low resolution mass spectrometric analysis. Peak identity was achieved by empirical formula determination while the quantitation was carried out using the extracted ion chromatograms of each analyte. After enzymatic hydrolysis of the urine, in the presence of deuterated internal standards, extraction of 22 benzodiazapines was accomplished using chIoroform/isopropanol (9:1). Separation of the individual benzodiazepines was achieved using a C8 LC column which provided adequate separation and the best peak shape. The analysis was carried out using a high resolution MS-TOF instrument which provided high sensitivity and specificity for all compounds tested. 2.0e4 ~ 
Results and Discussion
A procedure was developed for the simultaneous determination of the concentration of different benzodiazepines in urine using LC-MS-(TOF). The TOF MS provides accurate
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the intercept, the LOD, LOQ, and the percent recovery of each benzodiazepine at both the 25 ng/mL and 50 ng/mL levels. The procedure was linear for all the benzodiazepines with r ~ being > 0.999 in all cases. Figure I shows the calibration curves for all the compounds tested.
The high extraction efficiency, which ranged from approximately 84% to 98%, contributed to the high sensitivity of the method. The LOD and LOQ for all compounds tested ranged from 0.5 to 3 ng/mL and 2 to 10 ng/mL, respectively (Table I) .
Although 22 different benzodiazepines were tested in this procedure, only 6 deuterated internal standards were used, with each I.S. designated for specific analytes. Diazepam-d~ was 7-Amino-FNP-d 3 1"5e61 Nordiazepam-d5 was used as the internal standard for the analysis of nordiazepam and norfludiazepam. Figure 4 shows the selected chromatograms for the two analytes at 10 ng/mL extracted from urine in the presence of 100 ng/mL nordiazepam-ds. The full scan mass spectra are given with the high resolution measurements for the [M+H] § ions.
c~-Hydroxyalprazolam-ds was used as the internal standard for the analysis of triazolam, alprazolam, o~-OH-alprazolam, and ~-OH-triazolam. Figure 5 shows the selected ion chromatograms for the four analytes at 10 ng/mL extracted from urine in the presence of 100 ng/mL of their I.S. (o~-hydroxyalprazotam-ds). The full mass spectra for all analytes are given with the high resolution measurements of the [M+H] + ions.
Flunitrazepam-d7 was used as the internal standard for the analysis of nitrazepam, flunitrazepam, desmethyl-flunitrazepam, and 3-OH-flunitrazepam. Figure 6 shows the selected ion chromatograms for the four analytes at 10 ng/mL extracted from urine in the presence of 100 ng/mL of the I.S. (flunitrazepam-d7). The full mass spectra for all analytes are given with the high resolution measurements of the [M+H] § ions.
Finally, 7-aminoflunitrazepam-d3 was used as the internal standard for the analysis of 7-acetomidonorflunitrazepam, 7-aminoclonazepam, 7-aminonorflunitrazepam, 7-aminoflunitrazepam, and midazolam. FigUre 7 shows the selected ion chromatograms for the five analytes at 10 ng/mL extracted from urine in the presence of 100 ng/mL of the I.S. (7-aminoflunitrazepam-d3). The full mass spectra of all the analytes are given with the high resolution measurements for the [M+H] § ions.
As can be seen from Figures 2-7 , the chromatograms and the spectra for all analytes were of high quality at the 10 ng/mL level. Furthermore, Figure 8 shows the 0.5 ng/mL chromatogram and MS scans for triazolam and alprazolam in support of the LOD data shown in Table I . It must be mentioned that 0.5 ng/mL was the lowest level tested.
The procedure was used for the analysis of selected urine samples from sexual assault cases which were previously shown to be positive for benzodiazepines by immunoassay (50 ng/mL cut off with [3-glucronidase pre-incubation) but failed to confirm by a GC-MS method. Table II detected in sample 10. This suggests that the lack of GC-MS confirmation of these samples by the GC-MS method was because of the low levels of benzodiazepines in these samples or because the method did not include testing for these analytes, and not because of non-specific cross-reactivity of the immunoassay. In summary, a sensitive and specific LC-MS-(TOF) method has been developed and validated for the identification of very low levels of benzodiazepines in urine samples that could be applied to other biological specimens. Figure 10 . Extracted ion chromatograms and mass spectra of compounds extracted from urine sample #10 (ELI-62-16-16).
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